Testing effectiveness (Phase 2)Study completedNCT00023764
What this trial is testing
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Who this might be right for
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular Lymphoma+1 more
National Cancer Institute (NCI) 103